1h Free Analyst Time
Speak directly to the analyst to clarify any post sales queries you may have.
FEATURED COMPANIES
- AbbVie Inc.
- Astellas Pharma Inc.
- Cyxone AB
- F. Hoffmann La Roche Ltd.
- GlaxoSmithKline Plc
- Kangstem Biotech Co. Ltd.
1h Free Analyst Time
Speak directly to the analyst to clarify any post sales queries you may have.
The publisher has been monitoring the rheumatoid arthritis drugs market and it is poised to grow by $14.90 bn during 2022-2026, accelerating at a CAGR of 7.73% during the forecast period. The report on the rheumatoid arthritis drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by unmet needs for safer biologics for RA, the availability of improved diagnostic modalities, and the need for affordable biologics for RA.
The rheumatoid arthritis drugs market analysis includes the type segment and geographic landscape.
This study identifies the high cost of RA drugs as one of the prime reasons driving the rheumatoid arthritis drugs market growth during the next few years. Also, the use of biologics/biosimilars for the treatment of RA and the use of gene therapy for RA treatment will lead to sizable demand in the market.
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading rheumatoid arthritis drugs market vendors that include AbbVie Inc., Amgen Inc., Astellas Pharma Inc., Bristol Myers Squibb Co., Cyxone AB, Eli Lilly and Co., F. Hoffmann La Roche Ltd., Galmed Pharmaceuticals Ltd., Genor BioPharma Holding Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Johnson and Johnson, Kangstem Biotech Co. Ltd., Novartis AG, Oryn Therapeutics, Pfizer Inc., Sanofi, Sorrento Therapeutics Inc., Taisho Pharmaceutical Holdings Co. Ltd., and UCB SA. Also, the rheumatoid arthritis drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by unmet needs for safer biologics for RA, the availability of improved diagnostic modalities, and the need for affordable biologics for RA.
The rheumatoid arthritis drugs market analysis includes the type segment and geographic landscape.
The rheumatoid arthritis drugs market is segmented as below:
By Type
- Biologics
- Small molecules
By Geography
- Europe
- North America
- Asia
- Rest of World (ROW)
This study identifies the high cost of RA drugs as one of the prime reasons driving the rheumatoid arthritis drugs market growth during the next few years. Also, the use of biologics/biosimilars for the treatment of RA and the use of gene therapy for RA treatment will lead to sizable demand in the market.
The report on rheumatoid arthritis drugs market covers the following areas:
- Rheumatoid arthritis drugs market sizing
- Rheumatoid arthritis drugs market forecast
- Rheumatoid arthritis drugs market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading rheumatoid arthritis drugs market vendors that include AbbVie Inc., Amgen Inc., Astellas Pharma Inc., Bristol Myers Squibb Co., Cyxone AB, Eli Lilly and Co., F. Hoffmann La Roche Ltd., Galmed Pharmaceuticals Ltd., Genor BioPharma Holding Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Johnson and Johnson, Kangstem Biotech Co. Ltd., Novartis AG, Oryn Therapeutics, Pfizer Inc., Sanofi, Sorrento Therapeutics Inc., Taisho Pharmaceutical Holdings Co. Ltd., and UCB SA. Also, the rheumatoid arthritis drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Note: Product cover images may vary from those shown
FEATURED COMPANIES
- AbbVie Inc.
- Astellas Pharma Inc.
- Cyxone AB
- F. Hoffmann La Roche Ltd.
- GlaxoSmithKline Plc
- Kangstem Biotech Co. Ltd.
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Five Forces Analysis
5 Market Segmentation by Type
6 Customer Landscape
7 Geographic Landscape
8 Drivers, Challenges, and Trends
9 Vendor Landscape
10 Vendor Analysis
11 Appendix
List of Exhibits
Note: Product cover images may vary from those shown
FEATURED COMPANIES
- AbbVie Inc.
- Astellas Pharma Inc.
- Cyxone AB
- F. Hoffmann La Roche Ltd.
- GlaxoSmithKline Plc
- Kangstem Biotech Co. Ltd.
The publisher recognizes the following companies as the key players in the global rheumatoid arthritis drugs market: AbbVie Inc., Amgen Inc., Astellas Pharma Inc., Bristol Myers Squibb Co., Cyxone AB, Eli Lilly and Co., F. Hoffmann La Roche Ltd., Galmed Pharmaceuticals Ltd., Genor BioPharma Holding Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Johnson and Johnson, Kangstem Biotech Co. Ltd., Novartis AG, Oryn Therapeutics, Pfizer Inc., Sanofi, Sorrento Therapeutics Inc., Taisho Pharmaceutical Holdings Co. Ltd., and UCB SA.
Commenting on the report, an analyst from the research team said: `The latest trend gaining momentum in the market is high cost of RA drugs.`
According to the report, one of the major drivers for this market is the unmet needs for safer biologics for RA.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Commenting on the report, an analyst from the research team said: `The latest trend gaining momentum in the market is high cost of RA drugs.`
According to the report, one of the major drivers for this market is the unmet needs for safer biologics for RA.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
A selection of companies mentioned in this report includes:
- AbbVie Inc.
- Amgen Inc.
- Astellas Pharma Inc.
- Bristol Myers Squibb Co.
- Cyxone AB
- Eli Lilly and Co.
- F. Hoffmann La Roche Ltd.
- Galmed Pharmaceuticals Ltd.
- Genor BioPharma Holding Ltd.
- Gilead Sciences Inc.
- GlaxoSmithKline Plc
- Johnson and Johnson
- Kangstem Biotech Co. Ltd.
- Novartis AG
- Oryn Therapeutics
- Pfizer Inc.
- Sanofi
- Sorrento Therapeutics Inc.
- Taisho Pharmaceutical Holdings Co. Ltd.
- UCB SA
Note: Product cover images may vary from those shown
